Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area ...

Vertex Pharmaceuticals is expanding its manufacturing capabilities for its gene therapy Casgevy, signaling growing demand for the treatment. Business of Pride Join the Boston Business Journal for ...

Vertex Pharmaceuticals recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge related to its ...

Vertex reported Q1 revenue and earnings that fell well short of what most investors were anticipating. Higher costs were primarily responsible for the hit to earnings. Despite the headwinds ...